FDA PDUFA Goal Date Set for October 17, 2026RESEARCH TRIANGLE PARK, N.C., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, ...
The FDA accepted a supplemental new drug application to expand the indication for Ryzumvi to include the treatment of ...
Did you know that with the passage of time our sight fails more and more? However, there is a new prescription eye drop approved by the U.S. that promises to ...
Viatris Inc. (NASDAQ:VTRS) is one of the most undervalued stocks under $30 to buy. On February 25, Viatris announced that the ...
Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for ...
People with so-called "resting squint face" may seem like they are perpetually angry, but they may just be having trouble seeing. Focusing on close objects becomes increasingly difficult as people age ...
- Investigational, novel eye drop candidate was assigned PDUFA goal date of October 22, 2023 PONTE VEDRA, Fla., Feb. 21, 2023 /PRNewswire/ -- Orasis Pharmaceuticals, an emerging ophthalmic ...
LNZ100 shows superior efficacy and safety in presbyopia treatment, with a strong probability of FDA approval by August 2025. LNZ100 outperforms competitors Vuity and Qlosi, offering faster and greater ...
Presbyopia is defined as age-related loss of near vision that affects nearly everyone over age 45. The FDA has approved Vizz, an aceclidine ophthalmic solution 1.44%, making it the first and only ...
TearOptix, Inc., a pioneering contact lens company developing advanced solutions for patients with presbyopia, today announced the completion of a strategic corporate financing round led by investors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results